MG0020 ROZANOLIXIZUMAB: An Open-label, Crossover Study To Evaluate Rozanolixizumab Self-Administration by Study Participants with Generalized Myasthenia Gravis

Grants and Contracts Details

StatusActive
Effective start/end date2/27/233/7/25

Funding

  • Parexel International Co: $124,621.00